[Demyelinating disease].
Joko
Taisuke
T
Department of Psychiatry, Shinshu University School of Medicine.
Amano
Naoji
N
D000326:Adrenoleukodystrophy; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015551:Autoimmunity; D001569:Benzodiazepines; D002549:Diffuse Cerebral Sclerosis of Schilder; D004673:Encephalomyelitis, Acute Disseminated; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000209:etiology / Q000523:psychology / Q000628:therapy; D004676:Myelin Basic Protein / Q000276:immunology; D018991:Myelin Proteolipid Protein / Q000276:immunology; D009471:Neuromyelitis Optica; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020551:Pulse Therapy, Drug; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D008775:Methylprednisolone; D004676:Myelin Basic Protein; D018991:Myelin Proteolipid Protein; D000077152:Olanzapine; D010890:Pirenzepine; D017367:Selective Serotonin Reuptake Inhibitors